177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

In the Phase III study, the targeted radioligand therapy was associated with improved overall survival in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (median 15.3 v 11.3 months; HR 0.62; 95% CI 0.52-0.74; p<0.001).

Source:

GlobeNewswire